PolandPoland

More opposition to allowing national bans on GMOs

19.09.2010

Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not welcome, as it shifts responsibility from the Commission onto member states,” said Sa­wicki, after EU Health Commissioner John Dalli had presented a legally non-binding recommendation allowing a ban of GMO acreage through implementation of new GMO coexistence rules (see EuroBiotechNews 7-8/2010). “In effect, certain member states would maintain a ban on GMO crops while others would grow them. The renationalisation of EU decisions sets a bad precedent. Such solutions may result in disrupting competition between member states,” the Minister stated. Sa­wicki said his opposition was fundamental, since the Commission’s proposal leads to a diversification of agricultural production costs in different countries. “It is no secret that in Poland, France or Austria, social expectations are clearly in favour of us maintaining the existing ban on the production of GMOs,” he added. In the past, Sawicki has challenged the Commission not only to ban acreage of GMOs, but also to stop imports of other GM products, saying he thinks it “should take responsibility for the issue and state clearly that if we do not produce, then we should also not import GMO fodder.”

PolandPoland

09.05.2011

Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross...

PolandPoland

06.04.2011

Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...

PolandPoland

04.04.2011

Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...

PolandPoland

25.02.2011

Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...

PolandPoland

06.02.2011

Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...

PolandPoland

04.11.2010

Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...

PolandPoland

18.09.2010

Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...

PolandPoland

10.07.2010

Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...

PolandPoland

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...

PolandPoland

12.05.2010

Warsaw – Polish biotech firm Bioton SA wants to expand its business to Asia. At the end of April, the producer of recombinant insulin announced that it plans to issue convertible bonds worth EUR26m to fund an expansion of its...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/1/article/more-opposition-to-allowing-national-bans-on-gmos.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 12.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events